Suppliers and packagers for generic pharmaceutical drug: LENACAPAVIR SODIUM

LENACAPAVIR SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973	NDA	Gilead Sciences, Inc.	61958-3002-1	1 KIT in 1 CARTON (61958-3002-1) * 1.5 mL in 1 VIAL (61958-3004-1)	2022-12-22
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973	NDA	Gilead Sciences, Inc.	61958-3005-1	1 KIT in 1 CARTON (61958-3005-1) * 1.5 mL in 1 VIAL (61958-3004-1)	2025-03-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018	NDA	Gilead Sciences, Inc.	61958-3402-1	1 KIT in 1 CARTON (61958-3402-1) * 1.5 mL in 1 VIAL (61958-3403-1)	2025-06-18
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974	NDA	Gilead Sciences, Inc.	61958-3001-1	1 POUCH in 1 CARTON (61958-3001-1) / 1 BLISTER PACK in 1 POUCH / 4 TABLET, FILM COATED in 1 BLISTER PACK	2022-12-22
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974	NDA	Gilead Sciences, Inc.	61958-3001-2	1 POUCH in 1 CARTON (61958-3001-2) / 1 BLISTER PACK in 1 POUCH / 5 TABLET, FILM COATED in 1 BLISTER PACK	2022-12-22
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974	NDA	Gilead Sciences, Inc.	61958-3001-3	4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3001-3)	2022-12-22
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020	NDA	Gilead Sciences, Inc.	61958-3401-1	4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1)	2025-06-18

LENACAPAVIR SODIUM API SUPPLIERS AND MANUFACTURING LANDSCAPE

Last updated: February 19, 2026

This analysis details key suppliers and manufacturing capabilities for lenacapavir sodium, a long-acting HIV-1 capsid inhibitor. The information is critical for pharmaceutical companies, investors, and supply chain managers assessing manufacturing capacity, sourcing strategies, and competitive positioning.

WHO ARE THE PRIMARY API MANUFACTURERS FOR LENACAPAVIR SODIUM?

The primary active pharmaceutical ingredient (API) manufacturer for lenacapavir sodium is Gilead Sciences, the drug's originator. Gilead holds the foundational patents and controls the initial manufacturing process. However, as patent cliffs approach and market demand grows, the landscape is evolving to include contract development and manufacturing organizations (CDMOs) and potential generic manufacturers.

• Gilead Sciences: As the innovator, Gilead maintains proprietary manufacturing processes and likely holds significant internal manufacturing capacity. Their initial supply chain is centered around their established operations.
• Contract Development and Manufacturing Organizations (CDMOs): Pharmaceutical companies routinely outsource API production to specialized CDMOs. For lenacapavir sodium, specific CDMOs involved in its commercial-scale manufacturing are not publicly disclosed due to confidentiality agreements. However, companies with expertise in complex small molecule synthesis, chiral chemistry, and handling potent compounds are likely candidates. This includes organizations with capabilities in:
  • Multi-step organic synthesis
  • High-potency API (HPAPI) handling
  • Crystallization and solid-state characterization
  • Scale-up from clinical to commercial volumes
• Potential Generic Manufacturers: Following patent expiry, generic drug manufacturers will seek to produce lenacapavir sodium. These companies will either develop their own synthesis routes or license existing ones. Identifying these future players requires ongoing monitoring of patent litigation and market entry strategies.

WHAT ARE THE KEY TECHNOLOGICAL CONSIDERATIONS IN LENACAPAVIR SODIUM MANUFACTURING?

Lenacapavir sodium is a complex molecule requiring sophisticated synthesis and manufacturing processes. Key considerations include:

• Chiral Synthesis: The molecule likely contains chiral centers, necessitating stereoselective synthesis to produce the correct enantiomer. This requires specialized catalysts and reaction conditions.
• Multi-step Synthesis: The synthesis of lenacapavir sodium involves a significant number of chemical steps, each requiring optimization for yield, purity, and efficiency. This can impact overall cost of goods.
• Salt Formation: The API is formulated as a sodium salt, which influences its solubility, stability, and bioavailability. Controlled salt formation is critical for consistent drug product performance.
• Impurity Profiling and Control: Rigorous control of process-related impurities and degradation products is essential to meet regulatory standards. This involves advanced analytical techniques for detection and quantification.
• Potent Compound Handling: Like many modern pharmaceuticals, lenacapavir sodium may require specialized containment and handling procedures to protect personnel and the environment, classifying it as a high-potency API (HPAPI).

WHAT ARE THE PATENT LANDSCAPE AND EXPIRATION TIMELINES FOR LENACAPAVIR SODIUM?

The patent landscape for lenacapavir sodium is crucial for understanding market exclusivity and the timing of generic entry.

• Core Composition of Matter Patents: Gilead Sciences holds primary patents covering the lenacapavir molecule itself. These patents typically have a lifespan of 20 years from their filing date, subject to patent term extensions.
• Process Patents: Patents covering specific manufacturing processes, formulations, and methods of use also exist. These can extend market exclusivity beyond the core composition of matter patents.
• Key Patent Families and Expiration: While specific patent numbers and their exact expiration dates are complex and subject to regional variations and extensions, the general timeline for patent expiry dictates future market access. For example, U.S. Patent No. 9,945,411, related to lenacapavir, has an expected expiry around 2034, without considering potential extensions. ([1]) Other related patents are expected to expire in subsequent years.
• Patent Litigation and Challenges: As patents approach expiration, they become subject to challenges from potential generic manufacturers. This can involve Paragraph IV certifications in the U.S., which can lead to litigation and potentially earlier generic market entry.
• Regulatory Exclusivity: In addition to patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity in the U.S., Orphan Drug Exclusivity) can provide additional periods of market protection.

WHAT ARE THE REGULATORY REQUIREMENTS FOR LENACAPAVIR SODIUM MANUFACTURING?

Manufacturing lenacapavir sodium requires strict adherence to global regulatory standards.

• Good Manufacturing Practices (GMP): All manufacturing facilities and processes must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes stringent requirements for:
  • Quality management systems
  • Facility and equipment design and maintenance
  • Personnel training and hygiene
  • Material control and traceability
  • Production and process controls
  • Laboratory controls and testing
  • Documentation and record-keeping
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities. A DMF contains detailed information about the manufacturing process, quality control, and stability of the API. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary manufacturing details.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines provide a framework for harmonized regulatory requirements. Relevant ICH guidelines for API manufacturing include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
  • ICH Q11: Development and Manufacture of Drug Substances
  • ICH Q3A/B: Impurities in New Drug Substances/Products
• Environmental, Health, and Safety (EHS) Regulations: Given the potential for handling potent compounds, strict EHS protocols are mandatory. This includes waste management, emissions control, and occupational safety measures.

WHAT IS THE CURRENT AND PROJECTED MARKET DYNAMICS FOR LENACAPAVIR SODIUM MANUFACTURING CAPACITY?

The manufacturing capacity for lenacapavir sodium is influenced by Gilead's internal capabilities, CDMO partnerships, and anticipated generic competition.

• Current Capacity: Gilead Sciences' current internal capacity is designed to meet the initial demand for lenacapavir sodium. As a long-acting injectable, the dosage frequency is lower than daily oral medications, impacting the total volume of API required per patient annually.
• CDMO Role: Established CDMOs with advanced synthesis capabilities and GMP-compliant facilities are essential for scaling up production to meet global demand and potentially for supplying generic markets. Their involvement provides flexibility and access to specialized expertise.
• Projected Capacity Expansion: As lenacapavir sodium gains market traction and its therapeutic applications potentially expand, significant investments in expanding manufacturing capacity will be necessary. This could involve:
  • Gilead investing in its own facilities.
  • Strategic partnerships with multiple CDMOs.
  • Generic manufacturers building or securing their own production capabilities post-patent expiry.
• Supply Chain Resilience: Ensuring a robust and resilient supply chain is paramount. This involves diversifying suppliers, qualifying multiple manufacturing sites, and managing geopolitical risks that could disrupt production or distribution.
• Cost of Goods (COGS): The complexity of the synthesis, the specialized equipment required, and stringent quality control measures contribute to the COGS. Optimizing the manufacturing process and achieving economies of scale are critical for commercial success, especially with the advent of generic competition.

WHAT ARE THE KEY CONSIDERATIONS FOR SUPPLIER SELECTION AND QUALIFICATION?

Selecting and qualifying API suppliers for lenacapavir sodium involves a comprehensive evaluation process.

• Technical Expertise: Suppliers must demonstrate proven expertise in complex organic synthesis, chiral chemistry, and handling potent compounds. A strong track record in successful scale-up and GMP manufacturing is essential.
• Regulatory Compliance: Suppliers must have a history of successful regulatory inspections (FDA, EMA, etc.) and maintain robust quality management systems that meet global cGMP standards.
• Capacity and Scalability: The supplier's current capacity and their ability to scale up production to meet projected demand are critical. This includes their ability to handle batch sizes from clinical trial quantities to commercial volumes.
• Financial Stability: The financial health of potential suppliers is important to ensure long-term reliability and their ability to invest in necessary infrastructure and personnel.
• Supply Chain Security and Transparency: Suppliers must provide transparency into their own supply chains for raw materials and intermediates. Robust quality agreements and contingency plans for supply disruptions are necessary.
• Intellectual Property (IP) Protection: For innovator companies, ensuring that CDMOs maintain strict confidentiality and do not infringe on existing patents is paramount. For generic manufacturers, verifying that their chosen synthesis route does not infringe on active patents is crucial.
• Geographic Location: While not always the primary driver, proximity and geopolitical stability of manufacturing sites can influence supply chain logistics and risk mitigation.

KEY TAKEAWAYS

• Gilead Sciences is the primary originator and initial manufacturer of lenacapavir sodium API.
• CDMOs with expertise in complex organic synthesis, chiral chemistry, and HPAPI handling are critical partners for scale-up and commercial supply.
• The patent landscape, with core composition of matter patents extending into the mid-2030s, dictates the timeline for generic market entry.
• Manufacturing must adhere to stringent global cGMP standards, necessitating robust quality management systems and regulatory filings (e.g., DMFs).
• Key technological considerations include stereoselective synthesis, multi-step processes, salt formation, and impurity control.
• Supplier selection hinges on technical capability, regulatory compliance, capacity, financial stability, and supply chain security.

FREQUENTLY ASKED QUESTIONS

1. What is the typical lead time for qualifying a new API supplier for lenacapavir sodium?

The qualification process for a new API supplier typically ranges from 6 to 18 months. This period includes initial audits, quality agreement finalization, analytical method transfer, process validation, and successful GMP batch production.

2. How does the formulation of lenacapavir sodium as a salt impact its manufacturing requirements?

Formulating lenacapavir as a sodium salt requires precise control over the salt formation step to ensure consistent polymorphic form, particle size, and purity, all of which are critical for drug product dissolution and bioavailability. This step demands specialized crystallization and drying expertise.

3. Are there publicly available lists of CDMOs that manufacture lenacapavir sodium?

No, specific CDMOs contracted for lenacapavir sodium manufacturing are not publicly disclosed by Gilead Sciences due to confidentiality agreements. However, industry databases and market intelligence reports may identify CDMOs with relevant capabilities.

4. What are the primary analytical techniques used for quality control of lenacapavir sodium API?

Key analytical techniques include High-Performance Liquid Chromatography (HPLC) for assay and impurity profiling, Gas Chromatography (GC) for residual solvents, Mass Spectrometry (MS) for structural identification and impurity characterization, Nuclear Magnetic Resonance (NMR) for structural elucidation, Karl Fischer titration for water content, and Powder X-ray Diffraction (PXRD) for polymorphic form analysis.

5. How might the development of novel synthesis routes by generic manufacturers impact the current supply chain?

Generic manufacturers developing novel synthesis routes can impact the current supply chain by creating alternative sourcing options and potentially increasing overall market capacity. This can lead to price competition and may require original manufacturers to optimize their own processes for cost efficiency.

---

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from [USPTO website] (Specific patent number 9,945,411 search).